Meeting
2022 ASCO Annual Meeting
Platinum-free chemotherapy in the new era of immunotherapy: A phase II study of camrelizumab combined with apatinib and albumin paclitaxel in advanced non-squamous NSCLC (CAPAP-lung).
Authors
Lin Wu
Department of Thoracic Medicine, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
Lin Wu , Xingxiang Pu , Gen Lin , Maoliang Xiao , Jie Lin , Qianzhi Wang , Yi Kong , Xuejun Yan , Fang Xu , Yan Xu , Jia Li , Kang Li , bolin chen , Xiaoping Wen , Yali Tan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04459078
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9034)
DOI
10.1200/JCO.2022.40.16_suppl.9034
Abstract #
9034
Poster Bd #
22
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Camrelizumab monotherapy or in combination with apatinib for PD-L1-positive advanced pulmonary sarcomatoid carcinoma: A multicenter, open-label, single-arm, phase II study.
First Author: Mingfang Zhao
Poster
2019 ASCO Annual Meeting
Efficacy of PD-1 monoclonal antibody SHR-1210 plus apatinib in patients with advanced non-squamous NSCLC with wild‐type EGFR and ALK.
First Author: Caicun Zhou
Poster
2018 ASCO Annual Meeting
Phase II open-label, multi-centre study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC.
First Author: James Lorens
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Camrelizumab combined with apatinib and albumin-bound paclitaxel followed by camrelizumab plus apatinib as first-line therapy for unresectable or metastatic pancreatic cancer.
First Author: Bo Shen